TY - JOUR
T1 - All men with vasculogenic erectile dysfunction require a cardiovascular workup
AU - Miner, Martin
AU - Nehra, Ajay
AU - Jackson, Graham
AU - Bhasin, Shalender
AU - Billups, Kevin
AU - Burnett, Arthur L.
AU - Buvat, Jacques
AU - Carson, Culley
AU - Cunningham, Glenn
AU - Ganz, Peter
AU - Goldstein, Irwin
AU - Guay, Andre
AU - Hackett, Geoff
AU - Kloner, Robert A.
AU - Kostis, John B.
AU - Laflamme, K. Elizabeth
AU - Montorsi, Piero
AU - Ramsey, Melinda
AU - Rosen, Raymond
AU - Sadovsky, Richard
AU - Seftel, Allen
AU - Shabsigh, Ridwan
AU - Vlachopoulos, Charalambos
AU - Wu, Frederick
N1 - Funding Information:
Conflict of Interest: MM is a consultant to Abbott Laboratories, Chicago, IL, and conducts personal research for Forest Laboratories Inc, New York, NY, and Auxilium Pharmaceuticals Inc, Chesterbrook, PA. GJ is a speaker for Pfizer, New York, NY, Eli Lilly & Co, Indianapolis, IN, and Bayer, Leverkusen, Germany. KB is a consultant to Endo Pharmaceuticals, Chadds Ford, PA, and Abbott Laboratories. ALB is a consultant to Endo Pharmaceuticals, Abbott Laboratories, Timm Medical Technologies, Eden Prairie, MN, VIVUS Inc, Mountain View, CA, Auxilium Pharmaceuticals Inc., and Shionogi Inc., Florham Park, NJ; has received grant support from Pfizer; and has participated in clinical trials for VIVUS Inc and Auxilium Pharmaceuticals Inc.
Funding Information:
Funding: Editorial/medical writing support was provided by Melinda Ramsey and K. Elizabeth LaFlamme at Complete Healthcare Communications, Inc. and was funded by Pfizer.
PY - 2014/3
Y1 - 2014/3
N2 - An association between erectile dysfunction and cardiovascular disease has long been recognized, and studies suggest that erectile dysfunction is an independent marker of cardiovascular disease risk. Therefore, assessment and management of erectile dysfunction may help identify and reduce the risk of future cardiovascular events, particularly in younger men. The initial erectile dysfunction evaluation should distinguish between predominantly vasculogenic erectile dysfunction and erectile dysfunction of other etiologies. For men believed to have predominantly vasculogenic erectile dysfunction, we recommend that initial cardiovascular risk stratification be based on the Framingham Risk Score. Management of men with erectile dysfunction who are at low risk for cardiovascular disease should focus on risk-factor control; men at high risk, including those with cardiovascular symptoms, should be referred to a cardiologist. Intermediate-risk men should undergo noninvasive evaluation for subclinical atherosclerosis. A growing body of evidence supports the use of emerging prognostic markers to further understand cardiovascular risk in men with erectile dysfunction, but few markers have been prospectively evaluated in this population. In conclusion, we support cardiovascular risk stratification and risk-factor management in all men with vasculogenic erectile dysfunction.
AB - An association between erectile dysfunction and cardiovascular disease has long been recognized, and studies suggest that erectile dysfunction is an independent marker of cardiovascular disease risk. Therefore, assessment and management of erectile dysfunction may help identify and reduce the risk of future cardiovascular events, particularly in younger men. The initial erectile dysfunction evaluation should distinguish between predominantly vasculogenic erectile dysfunction and erectile dysfunction of other etiologies. For men believed to have predominantly vasculogenic erectile dysfunction, we recommend that initial cardiovascular risk stratification be based on the Framingham Risk Score. Management of men with erectile dysfunction who are at low risk for cardiovascular disease should focus on risk-factor control; men at high risk, including those with cardiovascular symptoms, should be referred to a cardiologist. Intermediate-risk men should undergo noninvasive evaluation for subclinical atherosclerosis. A growing body of evidence supports the use of emerging prognostic markers to further understand cardiovascular risk in men with erectile dysfunction, but few markers have been prospectively evaluated in this population. In conclusion, we support cardiovascular risk stratification and risk-factor management in all men with vasculogenic erectile dysfunction.
KW - Cardiovascular disease
KW - Erectile dysfunction
KW - Evaluation
UR - http://www.scopus.com/inward/record.url?scp=84894317154&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84894317154&partnerID=8YFLogxK
U2 - 10.1016/j.amjmed.2013.10.013
DO - 10.1016/j.amjmed.2013.10.013
M3 - Review article
C2 - 24423973
AN - SCOPUS:84894317154
SN - 0002-9343
VL - 127
SP - 174
EP - 182
JO - American Journal of Medicine
JF - American Journal of Medicine
IS - 3
ER -